162 related articles for article (PubMed ID: 25757922)
21. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.
Wu S; Zheng C; Chen S; Lin B; Chen Y; Zhou W; Li Z
Biochem Biophys Res Commun; 2015 Jan; 456(1):367-72. PubMed ID: 25475722
[TBL] [Abstract][Full Text] [Related]
22. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
23. Update on emerging treatments for chronic myeloid leukemia.
Fava C; Morotti A; Dogliotti I; Saglio G; Rege-Cambrin G
Expert Opin Emerg Drugs; 2015 Jun; 20(2):183-96. PubMed ID: 25826695
[TBL] [Abstract][Full Text] [Related]
24. Uptake of imatinib-loaded polyelectrolyte complexes by BCR-ABL(+) cells: a long-acting drug-delivery strategy for targeting oncoprotein activity.
Palamà IE; Coluccia AM; Gigli G
Nanomedicine (Lond); 2014 Jul; 9(14):2087-98. PubMed ID: 24364873
[TBL] [Abstract][Full Text] [Related]
25. The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription.
Ellis M; Krashin E; Hamburger-Avnery O; Gan S; Elis A; Ashur-Fabian O
Leuk Lymphoma; 2017 May; 58(5):1172-1177. PubMed ID: 27650030
[TBL] [Abstract][Full Text] [Related]
26. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
[TBL] [Abstract][Full Text] [Related]
27. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
28. The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.
Islamagic E; Hasic A; Kurtovic S; Suljovic Hadzimesic E; Mehinovic L; Kozaric M; Kurtovic-Kozaric A
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):238-240. PubMed ID: 28283298
[TBL] [Abstract][Full Text] [Related]
29. Pharmacology and pharmacokinetics of imatinib in pediatric patients.
Suttorp M; Bornhäuser M; Metzler M; Millot F; Schleyer E
Expert Rev Clin Pharmacol; 2018 Mar; 11(3):219-231. PubMed ID: 29076384
[TBL] [Abstract][Full Text] [Related]
30. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and preclinical evaluation of NRC-AN-019.
Amala K; Bhujanga Rao AK; Gorantla B; Gondi CS; Rao JS
Int J Oncol; 2013 Jan; 42(1):168-78. PubMed ID: 23151973
[TBL] [Abstract][Full Text] [Related]
32. Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients.
Suttorp M; Metzler M; Millot F; Shimada H; Bansal D; Günes AM; Kalwak K; Sedlacek P; Baruchel A; Biondi A; Hijiya N; Schultz KR; Schrappe M
Pediatr Blood Cancer; 2018 Dec; 65(12):e27431. PubMed ID: 30160364
[TBL] [Abstract][Full Text] [Related]
33. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
34. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
[TBL] [Abstract][Full Text] [Related]
35. Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells.
Palamà IE; Leporatti S; de Luca E; Di Renzo N; Maffia M; Gambacorti-Passerini C; Rinaldi R; Gigli G; Cingolani R; Coluccia AM
Nanomedicine (Lond); 2010 Apr; 5(3):419-31. PubMed ID: 20394535
[TBL] [Abstract][Full Text] [Related]
36. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
37. Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway.
Wang J; Li Q; Wang C; Xiong Q; Lin Y; Sun Q; Jin H; Yang F; Ren X; Pang T
Biochem Pharmacol; 2016 Jan; 99():132-45. PubMed ID: 26679828
[TBL] [Abstract][Full Text] [Related]
38. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
39. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
40. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
